<p>法国巴黎银行金融市场在最近向证券交易委员会（SEC）提交的 13F 文件中表示，在第四季度将其在西氏医药服务公司（NYSE:WST - 免费报告）的持股增加了 30.8%。该基金在季度内额外购买了 41,416 股后，持有 175,899 股该医疗器械供应商的股票。截至其最近向证券交易委员会（SEC）提交的文件，法国巴黎银行金融市场持有西氏医药服务公司 0.24% 的股份，价值 57,617,000 美元。</p>
<ul>
<li>3 只有潜力增加股息的股息冠军</li>
</ul>
<p>其他对冲基金最近也增加或减少了在该公司的持股。Whipplewood Advisors LLC 在第四季度以约 25,000 美元的估值新建了西氏医药服务公司的股份。Retirement Wealth Solutions LLC 在第四季度以约 34,000 美元的估值新建了西氏医药服务公司的股份。Centricity Wealth Management LLC 在第四季度以 35,000 美元的估值购买了西氏医药服务公司的股份。Cornerstone Planning Group LLC 在第四季度将其在西氏医药服务公司的股份增加了 57.1%。Cornerstone Planning Group LLC 现在拥有 110 股该医疗器械供应商的股票，价值 38,000 美元，此前在该期间内又购买了 40 股。最后，Private Trust Co. NA 在第四季度将其在西氏医药服务公司的股份增加了 138.6%。Private Trust Co. NA 现在拥有 136 股该医疗器械供应商的股票，价值 45,000 美元，此前在上个季度又购买了 79 股。93.90% 的股票由机构投资者和对冲基金持有。</p>
<h2>华尔街分析师预测增长</h2>
<p>多位分析师对 WST 股票发表了评论。德意志银行将西氏医药服务公司的评级从 “持有” 上调至 “买入”，并在 2 月 14 日的研究报告中设定了 250.00 美元的目标价。KeyCorp 将西氏医药服务公司的目标价从 470.00 美元下调至 325.00 美元，并在 2 月 14 日的研究报告中对该股票给予 “增持” 评级。Evercore ISI 在 3 月 18 日的研究报告中开始覆盖西氏医药服务公司的股票，给予 “跑赢大盘” 评级，并设定 275.00 美元的目标价。花旗集团在 1 月 8 日的报告中开始覆盖西氏医药服务公司的股票，给予 “买入” 评级，并设定 400.00 美元的目标价。最后，StockNews.com 在 2 月 27 日的报告中将西氏医药服务公司的股票评级从 “买入” 下调至 “持有”。两位分析师对该股票给予持有评级，六位给予买入评级，一位给予强烈买入评级。根据 MarketBeat 的数据，西氏医药服务公司的平均评级为 “适度买入”，平均目标价为 332.50 美元。</p>
<ul>
<li>今年将推动标准普尔 500 表现的因素是什么？</li>
</ul>
<p><strong>查看我们最新的 WST 股票报告</strong></p>
<h2>西氏医药服务公司的价格表现</h2>
<p>NYSE:WST 周三开盘价为 205.45 美元。该公司的 50 日移动平均价格为 217.46 美元，200 日移动平均价格为 279.88 美元。西氏医药服务公司在过去一年中的最低价为 187.43 美元，最高价为 372.52 美元。该公司的市值为 147.6 亿美元，市盈率为 30.71，市盈增长比率为 6.74，贝塔系数为 1.14。该公司的债务与股本比率为 0.08，流动比率为 2.79，速动比率为 2.23。</p>
<ul>
<li>至少有 30 年股息增长的医疗保健股票</li>
</ul>
<p>西氏医药服务公司（NYSE:WST - 获取免费报告）最近在 4 月 24 日发布了季度收益数据。该医疗器械供应商报告季度每股收益为 1.45 美元，超出分析师一致预期的 1.22 美元，超出幅度为 0.23 美元。西氏医药服务公司的净利润率为 17.03%，股本回报率为 18.60%。该公司在本季度的收入为 6.98 亿美元，而一致预期为 6.8524 亿美元。在去年同期，该公司每股收益为 1.56 美元。与去年同期相比，该公司的收入增长了 0.4%。股票研究分析师预测西氏医药服务公司将在当前年度发布 6.62 美元的每股收益。</p>
<h2>西氏医药服务公司宣布分红</h2>
<p>该公司最近还披露了一项季度分红，将于 8 月 6 日（星期三）支付。7 月 30 日（星期三）的股东将获得 0.21 美元的分红。这相当于年化分红为 0.84 美元，分红收益率为 0.41%。除息日为 7 月 30 日（星期三）。西氏医药服务公司的分红支付比率（DPR）目前为 13.19%。</p>
<h2>关于西氏医药服务公司</h2>
<p>（免费报告）</p>
<p>西氏医药服务公司设计、制造和销售用于注射药物和医疗保健产品的封闭和输送系统，业务遍及美洲、欧洲、中东、非洲和亚太地区。该公司分为两个部门，专有产品和合同制造产品。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过西氏医药服务公司</li>
<li>哪些华尔街分析师最准确？</li>
<li>3 只中型医疗股票表现优于市场</li>
<li>如何开始投资房地产</li>
<li>按市值排名的四月顶级内部购买</li>
<li>什么是国债？</li>
<li>在弱势收益和 CVS-Novo 合作后，礼来公司是否值得买入？</li>
</ul>
<p><strong>想看看其他对冲基金持有的 WST 吗？</strong> 访问 HoldingsChannel.com 获取西氏医药服务公司（NYSE:WST - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在西氏医药服务吗？</h2>
<p>在考虑西氏医药服务之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而西氏医药服务并不在名单上。</p>
<p>虽然西氏医药服务目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

西氏医药服务

<p>BNP Paribas 金融市场在第四季度将其在西氏医药服务公司（NYSE:WST）的持股比例增加了 30.8%，目前持有 175,899 股，价值 5760 万美元。其他对冲基金也调整了他们的持仓。分析师对 WST 的评级不一，目标价格范围在 250 美元到 400 美元之间。该股票开盘价为 205.45 美元，市值为 147.6 亿美元，市盈率为 30.71。公司报告每股收益为 1.45 美元，超出预期，并宣布季度股息为 0.21 美元</p>

<p>BNP Paribas Financial Markets increased its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) by 30.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 175,899 shares of the medical instruments supplier's stock after buying an additional 41,416 shares during the quarter. BNP Paribas Financial Markets owned 0.24% of West Pharmaceutical Services worth $57,617,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>法国巴黎银行金融市场在最近向证券交易委员会（SEC）提交的 13F 文件中表示，在第四季度将其在西氏医药服务公司（NYSE:WST - 免费报告）的持股增加了 30.8%。该基金在季度内额外购买了 41,416 股后，持有 175,899 股该医疗器械供应商的股票。截至其最近向证券交易委员会（SEC）提交的文件，法国巴黎银行金融市场持有西氏医药服务公司 0.24% 的股份，价值 57,617,000 美元。</p>
</div><ul>
<li>3 Dividend Champions with room for dividend growth</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只有潜力增加股息的股息冠军</li>
</ul>
</div><p>Other hedge funds also recently added to or reduced their stakes in the company. Whipplewood Advisors LLC acquired a new position in shares of West Pharmaceutical Services during the fourth quarter valued at about $25,000. Retirement Wealth Solutions LLC acquired a new position in West Pharmaceutical Services during the 4th quarter valued at approximately $34,000. Centricity Wealth Management LLC purchased a new position in shares of West Pharmaceutical Services in the fourth quarter worth $35,000. Cornerstone Planning Group LLC lifted its stake in shares of West Pharmaceutical Services by 57.1% during the fourth quarter. Cornerstone Planning Group LLC now owns 110 shares of the medical instruments supplier's stock worth $38,000 after buying an additional 40 shares during the period. Finally, Private Trust Co. NA grew its holdings in shares of West Pharmaceutical Services by 138.6% during the fourth quarter. Private Trust Co. NA now owns 136 shares of the medical instruments supplier's stock valued at $45,000 after buying an additional 79 shares during the last quarter. 93.90% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他对冲基金最近也增加或减少了在该公司的持股。Whipplewood Advisors LLC 在第四季度以约 25,000 美元的估值新建了西氏医药服务公司的股份。Retirement Wealth Solutions LLC 在第四季度以约 34,000 美元的估值新建了西氏医药服务公司的股份。Centricity Wealth Management LLC 在第四季度以 35,000 美元的估值购买了西氏医药服务公司的股份。Cornerstone Planning Group LLC 在第四季度将其在西氏医药服务公司的股份增加了 57.1%。Cornerstone Planning Group LLC 现在拥有 110 股该医疗器械供应商的股票，价值 38,000 美元，此前在该期间内又购买了 40 股。最后，Private Trust Co. NA 在第四季度将其在西氏医药服务公司的股份增加了 138.6%。Private Trust Co. NA 现在拥有 136 股该医疗器械供应商的股票，价值 45,000 美元，此前在上个季度又购买了 79 股。93.90% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of analysts have commented on WST shares. Deutsche Bank Aktiengesellschaft raised West Pharmaceutical Services from a &#34;hold&#34; rating to a &#34;buy&#34; rating and set a $250.00 price target for the company in a research report on Friday, February 14th. KeyCorp dropped their target price on West Pharmaceutical Services from $470.00 to $325.00 and set an &#34;overweight&#34; rating on the stock in a research report on Friday, February 14th. Evercore ISI initiated coverage on shares of West Pharmaceutical Services in a research report on Tuesday, March 18th. They set an &#34;outperform&#34; rating and a $275.00 price target for the company. Citigroup started coverage on shares of West Pharmaceutical Services in a report on Wednesday, January 8th. They issued a &#34;buy&#34; rating and a $400.00 price objective on the stock. Finally, StockNews.com cut shares of West Pharmaceutical Services from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Thursday, February 27th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, West Pharmaceutical Services has an average rating of &#34;Moderate Buy&#34; and an average target price of $332.50.</p>
<div class="lb-trans"><p>多位分析师对 WST 股票发表了评论。德意志银行将西氏医药服务公司的评级从 “持有” 上调至 “买入”，并在 2 月 14 日的研究报告中设定了 250.00 美元的目标价。KeyCorp 将西氏医药服务公司的目标价从 470.00 美元下调至 325.00 美元，并在 2 月 14 日的研究报告中对该股票给予 “增持” 评级。Evercore ISI 在 3 月 18 日的研究报告中开始覆盖西氏医药服务公司的股票，给予 “跑赢大盘” 评级，并设定 275.00 美元的目标价。花旗集团在 1 月 8 日的报告中开始覆盖西氏医药服务公司的股票，给予 “买入” 评级，并设定 400.00 美元的目标价。最后，StockNews.com 在 2 月 27 日的报告中将西氏医药服务公司的股票评级从 “买入” 下调至 “持有”。两位分析师对该股票给予持有评级，六位给予买入评级，一位给予强烈买入评级。根据 MarketBeat 的数据，西氏医药服务公司的平均评级为 “适度买入”，平均目标价为 332.50 美元。</p>
</div><ul>
<li>What Factors Will Drive S&amp;P 500 Performance This Year?</li>
</ul>
<div class="lb-trans"><ul>
<li>今年将推动标准普尔 500 表现的因素是什么？</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Report on WST</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 WST 股票报告</strong></p>
</div><h2>West Pharmaceutical Services Price Performance</h2>
<div class="lb-trans"><h2>西氏医药服务公司的价格表现</h2>
</div><p>NYSE:WST opened at $205.45 on Wednesday. The company has a 50 day moving average price of $217.46 and a 200-day moving average price of $279.88. West Pharmaceutical Services, Inc. has a 1-year low of $187.43 and a 1-year high of $372.52. The firm has a market cap of $14.76 billion, a price-to-earnings ratio of 30.71, a price-to-earnings-growth ratio of 6.74 and a beta of 1.14. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.79 and a quick ratio of 2.23.</p>
<div class="lb-trans"><p>NYSE:WST 周三开盘价为 205.45 美元。该公司的 50 日移动平均价格为 217.46 美元，200 日移动平均价格为 279.88 美元。西氏医药服务公司在过去一年中的最低价为 187.43 美元，最高价为 372.52 美元。该公司的市值为 147.6 亿美元，市盈率为 30.71，市盈增长比率为 6.74，贝塔系数为 1.14。该公司的债务与股本比率为 0.08，流动比率为 2.79，速动比率为 2.23。</p>
</div><ul>
<li>Healthcare Stocks With at Least 30 Years of Dividend Increases</li>
</ul>
<div class="lb-trans"><ul>
<li>至少有 30 年股息增长的医疗保健股票</li>
</ul>
</div><p>West Pharmaceutical Services (NYSE:WST - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The medical instruments supplier reported $1.45 earnings per share for the quarter, topping analysts' consensus estimates of $1.22 by $0.23. West Pharmaceutical Services had a net margin of 17.03% and a return on equity of 18.60%. The business had revenue of $698.00 million during the quarter, compared to the consensus estimate of $685.24 million. During the same quarter in the prior year, the firm posted $1.56 earnings per share. The company's revenue was up .4% compared to the same quarter last year. Equities research analysts forecast that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current year.</p>
<div class="lb-trans"><p>西氏医药服务公司（NYSE:WST - 获取免费报告）最近在 4 月 24 日发布了季度收益数据。该医疗器械供应商报告季度每股收益为 1.45 美元，超出分析师一致预期的 1.22 美元，超出幅度为 0.23 美元。西氏医药服务公司的净利润率为 17.03%，股本回报率为 18.60%。该公司在本季度的收入为 6.98 亿美元，而一致预期为 6.8524 亿美元。在去年同期，该公司每股收益为 1.56 美元。与去年同期相比，该公司的收入增长了 0.4%。股票研究分析师预测西氏医药服务公司将在当前年度发布 6.62 美元的每股收益。</p>
</div><h2>West Pharmaceutical Services Announces Dividend</h2>
<div class="lb-trans"><h2>西氏医药服务公司宣布分红</h2>
</div><p>The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 6th. Stockholders of record on Wednesday, July 30th will be given a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.41%. The ex-dividend date is Wednesday, July 30th. West Pharmaceutical Services's dividend payout ratio (DPR) is presently 13.19%.</p>
<div class="lb-trans"><p>该公司最近还披露了一项季度分红，将于 8 月 6 日（星期三）支付。7 月 30 日（星期三）的股东将获得 0.21 美元的分红。这相当于年化分红为 0.84 美元，分红收益率为 0.41%。除息日为 7 月 30 日（星期三）。西氏医药服务公司的分红支付比率（DPR）目前为 13.19%。</p>
</div><h2>About West Pharmaceutical Services</h2>
<div class="lb-trans"><h2>关于西氏医药服务公司</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.</p>
<div class="lb-trans"><p>西氏医药服务公司设计、制造和销售用于注射药物和医疗保健产品的封闭和输送系统，业务遍及美洲、欧洲、中东、非洲和亚太地区。该公司分为两个部门，专有产品和合同制造产品。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than West Pharmaceutical Services</li>
<li>Which Wall Street Analysts are the Most Accurate?</li>
<li>3 Mid-Cap Medical Stocks Outperforming the Market</li>
<li>How to Start Investing in Real Estate</li>
<li>The Top-Ranked Insider Buys From April by Market Cap</li>
<li>What Are Treasury Bonds?</li>
<li>Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过西氏医药服务公司</li>
<li>哪些华尔街分析师最准确？</li>
<li>3 只中型医疗股票表现优于市场</li>
<li>如何开始投资房地产</li>
<li>按市值排名的四月顶级内部购买</li>
<li>什么是国债？</li>
<li>在弱势收益和 CVS-Novo 合作后，礼来公司是否值得买入？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding WST?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 WST 吗？</strong> 访问 HoldingsChannel.com 获取西氏医药服务公司（NYSE:WST - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=WST"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in West Pharmaceutical Services Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在西氏医药服务吗？</h2>
</div><p>Before you consider West Pharmaceutical Services, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑西氏医药服务之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而西氏医药服务并不在名单上。</p>
</div><p>While West Pharmaceutical Services currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然西氏医药服务目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

法国巴黎银行金融市场增持了西氏医药服务公司（NYSE:WST）的股份